Algert Global LLC Takes $88,000 Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Algert Global LLC acquired a new position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) in the fourth quarter, Holdings Channel reports. The fund acquired 10,360 shares of the specialty pharmaceutical company’s stock, valued at approximately $88,000.

Several other institutional investors have also made changes to their positions in the business. Aquatic Capital Management LLC acquired a new position in KalVista Pharmaceuticals in the fourth quarter worth about $44,000. Tower Research Capital LLC TRC boosted its holdings in KalVista Pharmaceuticals by 666.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company’s stock valued at $54,000 after purchasing an additional 5,502 shares in the last quarter. Legal & General Group Plc boosted its holdings in KalVista Pharmaceuticals by 22.5% during the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company’s stock valued at $69,000 after purchasing an additional 1,494 shares in the last quarter. Martin Worley Group bought a new stake in shares of KalVista Pharmaceuticals in the 4th quarter valued at approximately $86,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of KalVista Pharmaceuticals by 24.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock worth $87,000 after buying an additional 2,043 shares in the last quarter.

KalVista Pharmaceuticals Stock Performance

KalVista Pharmaceuticals stock opened at $11.64 on Wednesday. The business’s fifty day moving average is $12.05 and its two-hundred day moving average is $10.42. The firm has a market cap of $578.69 million, a P/E ratio of -3.20 and a beta of 0.05. KalVista Pharmaceuticals, Inc. has a 52 week low of $7.30 and a 52 week high of $15.50.

Insider Activity at KalVista Pharmaceuticals

In related news, major shareholder Venrock Healthcare Capital Par purchased 25,000 shares of the stock in a transaction that occurred on Wednesday, April 9th. The stock was acquired at an average price of $9.42 per share, with a total value of $235,500.00. Following the completion of the acquisition, the insider now directly owns 5,303,985 shares in the company, valued at approximately $49,963,538.70. This trade represents a 0.47% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Paul K. Audhya sold 3,125 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total transaction of $30,687.50. Following the completion of the transaction, the insider now owns 100,334 shares of the company’s stock, valued at $985,279.88. This trade represents a 3.02% decrease in their position. The disclosure for this sale can be found here. Insiders sold 17,292 shares of company stock valued at $184,625 over the last ninety days. 10.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on KALV shares. Needham & Company LLC restated a “buy” rating and set a $28.00 target price on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 8th. JMP Securities started coverage on KalVista Pharmaceuticals in a research note on Friday, January 31st. They set an “outperform” rating and a $19.00 price objective for the company. Jones Trading reissued a “buy” rating and set a $30.00 price objective on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a report on Friday, March 14th. Finally, Citizens Jmp upgraded shares of KalVista Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 31st. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $24.83.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).